The three pathways that we investigated as contributors (pinocytosis, alkalinisation, elastase) to probe activation in vitro, may be further dissected by dose–response experiments and/or by using different combinations of NADPH oxidase inhibitors and ROS scavengers or neutrophils from patients with chronic granulomatous disease (CGD). Here, FMO5 is linked to chronic granulomatous disease.